Form D · Biotechnology
Way Biosolutions, Inc.
Cambridge, MA · CIK 0002155613
Offering snapshot reported Sep 25, 2026 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 14, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2026 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598863
Simple Agreement for Future Equity
Source: Form D, filed Sep 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Meister | Director |
| David R. Walt | Director |
| Huaibin Zhang | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Acorn Park Drive Suite 501
Cambridge, MA, 02140
Phone: 5082907699
Cambridge, MA, 02140
Phone: 5082907699